Teva Pharmaceutical Industries Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TEVA research report →
Range $44 – $54
Price Chart
About the company
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs).
- CEO
- Richard D. Francis
- IPO
- 1982
- Employees
- 32,008
- HQ
- Tel Aviv, TA, IL
Get TickerSpark's AI analysis on TEVA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $45.77B
- P/E
- 87.18
- Fwd P/E
- 18.97
- PEG
- -3.05
- P/S
- 2.66
- P/B
- 5.73
- EV/EBITDA
- 28.76
- Div Yield
- 0.00%
- Gross Margin
- 53.52%
- Op Margin
- 8.33%
- Net Margin
- 2.94%
- ROE
- 6.35%
- ROIC
- 5.01%
Latest fiscal year · YoY change
- Revenue
- $17.26B+4.3%
- Gross Profit
- $8.94B+10.9%
- Op Income
- $2.16B
- Net Income
- $1.41B+186.0%
- EPS
- $1.23+184.8%
- OCF Growth
- +32.2%
- FCF Growth
- +53.3%
- 52W High
- $44.57
- 52W Low
- $24.01
- 50D MA
- $40.58
- 200D MA
- $35.23
- Beta
- 0.84
- RSI (14)
- 40
- Avg Volume
- 6.27M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Teva delivered a strong Q3 on innovative-product growth, margin expansion, and raised full-year guidance, while also advancing its pipeline and capital-return profile.· November 3, 2026
- Innovative products led the quarter: AUSTEDO, UZEDY and AJOVY all grew strongly, with the innovative portfolio up 33%.
- Gross margin expanded to 58.7% in Q3, up 345 basis points year over year, as mix shifted toward higher-margin innovative products.
- Teva raised full-year guidance for AUSTEDO, UZEDY, AJOVY, revenue, EBITDA, EPS and free cash flow.
- Management said Teva is on track for investment-grade balance-sheet goals, with $4.9 billion of senior notes refinanced and no borrowings outstanding on the revolver.
- Pipeline news was mixed: WELTRUZA was approved, ecopipam and BXCL501 remain key near-term programs, and emrusolmin was discontinued after a futility analysis with no safety concerns.
Q3 revenue was approximately $4.4 billion, down 2% year over year. Non-GAAP gross margin was 58.7%, up 345 basis points year over year, and non-GAAP EPS was $0.86, up 10% year over year. EBITDA grew 7%. GAAP net profit was $233 million and GAAP EPS was $0.20. By product, AUSTEDO revenue was $751 million, up 21%; UZEDY was $85 million, up 96%; and AJOVY was $269 million, up 61%. Full-year 2026 guidance was raised to revenue of $16.7 billion-$17 billion, gross margin of 54.5%-55.5%, operating income of $3.8 billion-$3.9 billion, adjusted EBITDA of $4.23 billion-$4.43 billion, diluted EPS of $1.92-$2.11, and free cash flow of $2.1 billion-$2.4 billion. Product guidance was also raised: AUSTEDO to $2.55 billion-$2.65 billion, UZEDY to $290 million-$310 million, and AJOVY to $930 million-$960 million. Management said Q4 AUSTEDO should be down year over year because of purchasing patterns and IRA timing, and WELTRUZA should not be a major revenue contributor in Q4 or the first half of 2027, with revenue expected in the latter half of 2027.
Richard Francis framed the quarter as evidence that Teva’s “pivot to growth” is working, saying the company is transitioning from a generic drug company to a biopharma company. He emphasized strong execution in the innovative portfolio, described WELTRUZA as an important schizophrenia launch, and highlighted a broad pipeline with biosimilars, neuroscience and immunology assets. His tone was upbeat and confident, but he also acknowledged the emrusolmin discontinuation was disappointing and stressed that Teva’s growth and margin trajectory is being driven by deliberate strategic choices.
Eli Kalif focused on the financial transformation: Q3 revenue was about $4.4 billion, non-GAAP gross margin was 58.7%, and non-GAAP EPS was $0.86. He said free cash flow was $495 million in the quarter and that Teva repaid about $1.8 billion of debt maturity in October, with no amount outstanding on the revolver. He also reiterated the company’s path to a 30% operating margin by 2027, noted updated 2026 operating margin guidance of 27.8%-28.2% excluding IPR&D, and said Teva expects about $700 million of transformation savings, with roughly two-thirds tied to OpEx and the rest to network optimization and COGS. He highlighted capital flexibility from improved working capital and lower interest expense, and said the company remains focused on debt reduction, investment-grade status, and selective capital deployment.
Analysts pressed management on how Teva can expand gross margin toward 57%-58% in 2027 even if AUSTEDO faces IRA pressure, and management said the answer is a mix of portfolio shift, transformation savings, manufacturing/network optimization, and additional innovative launches. Questions also focused on WELTRUZA’s uptake timing, with management saying meaningful revenue is more likely in the second half of 2027 because Medicaid formulary access will take time. On biosimilars, management said litigation risk is expected in the category but does not derail Teva’s plans, and they confirmed they are building launch readiness without committing to any specific launch outcome. Analysts also asked about ecopipam, BXCL501, TL1A, and M&A; management generally deferred detailed 2027 pipeline guidance to next week’s R&D day, while saying BD/M&A will remain disciplined and value-focused.
The bull case from the call is that Teva’s innovative franchise is scaling faster than expected, with AUSTEDO, UZEDY and AJOVY all being raised and management now expecting the company to keep growing beyond 2027. Margin expansion and cash generation also appear to be improving, supported by a stronger mix, transformation savings, investment-grade balance sheet status, and lower debt. The pipeline and biosimilar portfolio add multiple shots on goal, with WELTRUZA now approved and additional catalysts coming at the R&D day.
The main risks discussed were dependence on a few growth brands, especially AUSTEDO, as well as the IRA’s impact on next year’s economics and WELTRUZA’s slow revenue ramp because of access constraints. Generics remain pressured, with management saying the business is held back by generic REVLIMID and that litigation could affect biosimilar timing. Pipeline execution is also still uncertain: emrusolmin was discontinued, and management declined to give detailed 2027 revenue contributions for some newer assets like ecopipam and BXCL501.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.1%
- Shares Outstanding
- 1.17B
- Float Shares
- 1.11B
of shares held by institutions
718 13F filers
Buy/sell ratio 0.59. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for TEVA, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 63.42M | ▼ 474.37K |
| Phoenix Financial Ltd. | 42.63M | ▼ 307.42K |
| Wcm Investment Management, LLC | 42.25M | ▲ 938.24K |
| Clal Insurance Enterprises Holdings Ltd | 42.09M | ▲ 1.50M |
| Menora Mivtachim Holdings Ltd. | 39.85M | ▲ 228.00K |
| Migdal Insurance & Financial Holdings Ltd. | 39.42M | ▲ 500.00K |
| Harel Insurance Investments & Financial Services Ltd. | 34.66M | ▼ 13.48M |
| Vanguard Capital Management LLC | 32.52M | ▲ 32.51M |
| Norges Bank | 32.30M | ▲ 32.30M |
| Fmr LLC | 25.78M | ▼ 4.47M |
| State Street Corp | 19.31M | ▲ 372.56K |
| Capital World Investors | 18.01M | ▲ 5.47M |
Held by 447 ETFs
Biggest fund positions in TEVA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 15, 26 | Bergwerk Dov | other | 8,370 |
| Nov 15, 26 | Bergwerk Dov | other | 8,370 |
| Nov 9, 26 | Daniell Richard | other | 25,000 |
| Nov 11, 26 | Daniell Richard | other | 20,003 |
| Nov 9, 26 | Daniell Richard | sell | 25,000 |
| Nov 11, 26 | Daniell Richard | sell | 20,003 |
| Nov 9, 26 | Daniell Richard | other | 25,000 |
| Nov 11, 26 | Daniell Richard | other | 20,003 |
| Nov 10, 26 | Francis Richard D | sell | 250,000 |
| Nov 12, 26 | Sabag Mark | other | 44,710 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TEVA coverage
Recent articles, reports, and earnings notes.
No research on TEVA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TEVA report →Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi's 2026 Global Healthcare Conference
globenewswire.com · Nov 20
Teva Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Teva (TEVA)
prnewswire.com · Nov 20
Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company
globenewswire.com · Nov 18
David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes
benzinga.com · Nov 17
FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder
benzinga.com · Nov 16
Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030
marketbeat.com · Nov 11
Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030
globenewswire.com · Nov 11
Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?
fool.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.